7月9日,南通联亚药业股份有限公司(简称“联亚药业”)在深圳证券交易所(简称“深交所”)IPO上会获通过。此次联亚药业在创业板IPO上会通过,也是沪深交易所近年来首家仿制药IPO企业。在当日的审议会议现场,深交所上市委员会要求联亚药业结合自身琥珀酸美托洛尔缓释片等产品境外销售情况、市占率、价格变化以及发行人与第一大客户收益分成机制主要内容等,说明上述因素对境外收入稳定性的影响,联亚药业的应对措施及...
Source Link7月9日,南通联亚药业股份有限公司(简称“联亚药业”)在深圳证券交易所(简称“深交所”)IPO上会获通过。此次联亚药业在创业板IPO上会通过,也是沪深交易所近年来首家仿制药IPO企业。在当日的审议会议现场,深交所上市委员会要求联亚药业结合自身琥珀酸美托洛尔缓释片等产品境外销售情况、市占率、价格变化以及发行人与第一大客户收益分成机制主要内容等,说明上述因素对境外收入稳定性的影响,联亚药业的应对措施及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.